Contrast-enhanced Ultrasound With Perfluorobutane and Sulfur Hexafluoride for Hepatocellular Carcinoma

Seoul National University

Status: Completed

Conditions: Hepatocellular Carcinoma

Treatments: Diagnostic Test: contrast enhanced ultrasound; Diagnostic Test: Liver MRI; Diagnostic Test: Dynamic CT

Study type: Interventional

Funder types: Other

Identifiers

NCT04847726

SNUH-1807-166

Details and patient eligibility

About

Intra-individual comparison of diagnostic performance of CEUS With perfluorobutane and sulfur hexafluoride for HCC in high-risk Individuals, and their role in the diagnostic algorithm of HCC.

Full description

The investigators would compare the diagnostic performance for HCC at high-risk individuals between both USG contrast agents.

Enrollment: 110 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• high-risk for HCC (liver cirrhosis, chronic hepatitis B)
• treatment-naive hepatic nodule (>= 1cm) on preceding CT, MR or ultrasound

Exclusion criteria

• severe cardiopulmonary dysfunction
• pregnancy
• refusal to enroll study

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

110 participants in 1 patient group

CEUS with perfluorobutane and sulfur hexafluoride

Experimental group

Description:

Contrast-enhanced ultrasound with perfluorobutane and sulfur hexafluoride for the hepatic lesion.

Treatment:

Diagnostic Test: Liver MRI

Diagnostic Test: contrast enhanced ultrasound

Diagnostic Test: Dynamic CT